| Document and Entity Information - shares | 6 Months Ended | |
| Jun. 30, 2024 | Jul. 29, 2024 |
| Cover [Abstract] | | |
| Document Type | 10-Q/A | |
| Amendment Description | This Amendment No. 1 on Form 10-Q/A (this “Amendment No. 1") hereby amends the Quarterly Report on Form 10-Q of Athira Pharma, Inc. (the “Company”) for the quarterly period ended June 30, 2024 (the “Original Form 10-Q”), filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 1, 2024. This Amendment No. 1 is being filed solely to include Exhibits 10.1 and 10.2 to the Form 10-Q/A, which were inadvertently omitted in the Original Form 10-Q.In accordance with applicable SEC rules, this Amendment No. 1 also contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated as of the date of filing of this Amendment No. 1. Because this Amendment No. 1 does not include financial statements and does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the Section 302 certifications have been omitted. Accordingly, this Amendment No. 1 consists solely of the preceding cover page, this explanatory note, Part II, Item 6 “Exhibits,” in its entirety, the signature page, and Exhibits 10.1, 10.2, 31.3 and 31.4. Except as expressly set forth in this Amendment No. 1, no other changes have been made to the Original Form 10-Q, and this Amendment No. 1 does not modify or update in any way the financial position, results of operations, cash flows or other disclosures in, or exhibits to, the Original Form 10-Q, nor does it reflect events occurring after the filing of the Original Form 10-Q. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Form 10-Q and with the Company’s filings with the SEC subsequent to the filing of the Original Form 10-Q. | |
| Amendment Flag | true | |
| Document Period End Date | Jun. 30, 2024 | |
| Document Fiscal Year Focus | 2024 | |
| Document Fiscal Period Focus | Q2 | |
| Entity Registrant Name | Athira Pharma, Inc. | |
| Entity Central Index Key | 0001620463 | |
| Entity Current Reporting Status | Yes | |
| Entity Interactive Data Current | Yes | |
| Current Fiscal Year End Date | --12-31 | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Common Stock, Shares Outstanding | | 38,439,375 |
| Entity Shell Company | false | |
| Entity Small Business | true | |
| Entity Emerging Growth Company | true | |
| Entity Ex Transition Period | false | |
| Entity File Number | 001-39503 | |
| Entity Incorporation, State or Country Code | DE | |
| Entity Tax Identification Number | 45-3368487 | |
| Entity Address, Address Line One | 18706 North Creek Parkway | |
| Entity Address, Address Line Two | Suite 104 | |
| Entity Address, City or Town | Bothell | |
| Entity Address, State or Province | WA | |
| Entity Address, Postal Zip Code | 98011 | |
| City Area Code | 425 | |
| Local Phone Number | 620-8501 | |
| Document Quarterly Report | true | |
| Document Transition Report | false | |
| Security12b Title | Common Stock, $0.0001 par value per share | |
| Trading Symbol | ATHA | |
| Security Exchange Name | NASDAQ | |
